A next-generation STING agonist MSA-2: From mechanism to application

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• The stimulator of interferon genes (STING) pathway is crucial for innate and adaptive immunity, particularly in antitumor responses.
• Existing STING agonists, including endogenous and cyclic dinucleotide (CDN)-derived compounds, have shown limitations in efficacy or clinical success for cancer immunotherapy.
• The identification of MSA-2, a non-nucleotide STING agonist, in 2020 marked a significant advancement, demonstrating potent antitumor effects in preclinical models and oral bioavailability.

Purpose of the Study:

• To provide a comprehensive review of the non-nucleotide STING agonist MSA-2 and its derivatives.
• To summarize recent research on MSA-2, including its structure-activity relationships, delivery systems, and combination therapy applications.
• To highlight interventional strategies based on MSA-2 to guide future research in cancer immunotherapy.

Main Methods:

• Literature review of studies on MSA-2 and related STING agonists.
• Analysis of structure-activity relationships and pharmacokinetic properties of MSA-2.
• Synthesis of information on preclinical and potential clinical applications of MSA-2 in cancer treatment.

Main Results:

• MSA-2 exhibits a distinctive binding mode and enhanced bioavailability compared to other STING agonists.
• Preclinical studies demonstrate satisfactory antitumor effects of MSA-2, with potential for oral administration.
• Research on MSA-2 derivatives is expanding, covering diverse aspects from molecular interactions to therapeutic strategies.

Conclusions:

• MSA-2 represents a promising new class of STING agonists for cancer immunotherapy.
• Its favorable properties, including oral bioavailability and potent antitumor activity, warrant further investigation.
• This review provides a foundation for future research and development of MSA-2-based cancer therapies.